The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The India vs Pakistan clash in the ICC T20 World Cup is one of the…
The Reserve Bank of India (RBI) has issued draft guidelines allowing banks to lend to…
Vast Space, a privately-held American aerospace company, has signed an order with NASA for its…
The Reserve Bank of India (RBI) has revised its draft guidelines on acquisition financing, allowing…
Veteran Kannada filmmaker Joe Simon passed away on Friday after suffering a sudden cardiac arrest…
India–Pakistan matches in the T20 World Cup are always high-pressure contests, and several Indian batters…